DBC-664

DBC-664 is a Claudin 6 (CLDN6)-targeted antibody-drug conjugate (ADC) developed by Duboce Biopharmaceuticals for the treatment of advanced solid tumors. It consists of a humanized monoclonal antibody specific for CLDN6 conjugated to a topoisomerase I inhibitor payload (an exatecan derivative) via a protease-cleavable linker. CLDN6 is a tight junction protein that is highly expressed in various fetal tissues but largely absent in healthy adult tissues, while being overexpressed in several cancers, including ovarian, endometrial, and lung cancers, making it an attractive therapeutic target. DBC-664 is designed to selectively deliver its cytotoxic payload to tumor cells, inducing DNA damage and apoptosis. It is currently undergoing Phase 1 clinical evaluation in patients with locally advanced or metastatic solid tumors that express CLDN6.